Concepts (219)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 2 | 66 | 2023 | 592 | 14.240 |
Why?
|
| Hypoglycemic Agents | 41 | 2023 | 152 | 8.220 |
Why?
|
| Insulin | 21 | 2022 | 224 | 7.380 |
Why?
|
| Diabetes Mellitus | 34 | 2022 | 465 | 7.190 |
Why?
|
| Prediabetic State | 10 | 2023 | 51 | 5.880 |
Why?
|
| Blood Glucose | 31 | 2023 | 333 | 3.880 |
Why?
|
| Thiazolidinediones | 10 | 2020 | 48 | 3.660 |
Why?
|
| Cardiovascular Diseases | 8 | 2023 | 628 | 2.610 |
Why?
|
| Blood Glucose Self-Monitoring | 9 | 2019 | 28 | 2.560 |
Why?
|
| Diabetes Mellitus, Type 1 | 8 | 2019 | 58 | 2.510 |
Why?
|
| Metformin | 6 | 2020 | 64 | 2.200 |
Why?
|
| Humans | 111 | 2023 | 34853 | 2.070 |
Why?
|
| Life Style | 6 | 2023 | 288 | 1.720 |
Why?
|
| Glucose Intolerance | 5 | 2023 | 42 | 1.520 |
Why?
|
| Glucose Tolerance Test | 9 | 2012 | 66 | 1.480 |
Why?
|
| Primary Health Care | 4 | 2017 | 283 | 1.470 |
Why?
|
| Insulin Resistance | 5 | 2013 | 177 | 1.370 |
Why?
|
| Hyperglycemia | 6 | 2022 | 53 | 1.350 |
Why?
|
| Patient Education as Topic | 7 | 2017 | 207 | 1.320 |
Why?
|
| Diabetic Retinopathy | 3 | 2016 | 65 | 1.310 |
Why?
|
| Societies, Medical | 10 | 2014 | 62 | 1.210 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2017 | 63 | 1.130 |
Why?
|
| Research Support as Topic | 5 | 2004 | 75 | 1.120 |
Why?
|
| Algorithms | 10 | 2012 | 435 | 1.110 |
Why?
|
| Quality of Life | 5 | 2014 | 459 | 0.980 |
Why?
|
| Fasting | 9 | 2020 | 50 | 0.960 |
Why?
|
| Middle Aged | 28 | 2020 | 9642 | 0.950 |
Why?
|
| Vitamin D | 3 | 2021 | 176 | 0.950 |
Why?
|
| Adult | 22 | 2023 | 11034 | 0.950 |
Why?
|
| Diabetes Complications | 3 | 2009 | 91 | 0.930 |
Why?
|
| Male | 35 | 2020 | 18870 | 0.920 |
Why?
|
| Female | 33 | 2020 | 19873 | 0.810 |
Why?
|
| Sulfonylurea Compounds | 2 | 2019 | 12 | 0.790 |
Why?
|
| Minority Groups | 4 | 2007 | 537 | 0.760 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2019 | 4 | 0.740 |
Why?
|
| Hydroxychloroquine | 1 | 2019 | 15 | 0.730 |
Why?
|
| Urinary Tract Infections | 1 | 2019 | 36 | 0.710 |
Why?
|
| Aged | 16 | 2019 | 6448 | 0.700 |
Why?
|
| Risk Factors | 11 | 2023 | 3414 | 0.690 |
Why?
|
| Self Care | 6 | 2017 | 150 | 0.670 |
Why?
|
| Randomized Controlled Trials as Topic | 7 | 2014 | 233 | 0.660 |
Why?
|
| Albuminuria | 2 | 2011 | 76 | 0.640 |
Why?
|
| Clinical Protocols | 1 | 2017 | 34 | 0.630 |
Why?
|
| Insulin Infusion Systems | 1 | 2017 | 3 | 0.610 |
Why?
|
| Cholesterol, LDL | 5 | 2017 | 63 | 0.600 |
Why?
|
| United States | 19 | 2014 | 3894 | 0.590 |
Why?
|
| Obesity | 4 | 2022 | 965 | 0.580 |
Why?
|
| Cost-Benefit Analysis | 6 | 2020 | 142 | 0.580 |
Why?
|
| Weight Loss | 3 | 2023 | 124 | 0.540 |
Why?
|
| Reminder Systems | 2 | 2005 | 12 | 0.520 |
Why?
|
| Health Transition | 1 | 2014 | 5 | 0.500 |
Why?
|
| Sertraline | 2 | 2011 | 7 | 0.500 |
Why?
|
| Drug Therapy, Combination | 6 | 2019 | 217 | 0.490 |
Why?
|
| Disease Management | 3 | 2014 | 61 | 0.490 |
Why?
|
| Dyslipidemias | 1 | 2014 | 42 | 0.490 |
Why?
|
| Outsourced Services | 2 | 2004 | 5 | 0.480 |
Why?
|
| Diabetes, Gestational | 2 | 2020 | 46 | 0.480 |
Why?
|
| Double-Blind Method | 4 | 2023 | 269 | 0.480 |
Why?
|
| Antidepressive Agents | 2 | 2011 | 53 | 0.480 |
Why?
|
| Delivery of Health Care | 3 | 2009 | 254 | 0.470 |
Why?
|
| Reproducibility of Results | 9 | 2010 | 901 | 0.460 |
Why?
|
| Glucose Clamp Technique | 1 | 2013 | 7 | 0.460 |
Why?
|
| Nursing Care | 2 | 2010 | 6 | 0.450 |
Why?
|
| Blood Pressure | 6 | 2017 | 613 | 0.440 |
Why?
|
| Research Design | 1 | 2014 | 292 | 0.430 |
Why?
|
| Pyrazines | 1 | 2011 | 23 | 0.410 |
Why?
|
| Pharmacists | 2 | 2009 | 53 | 0.400 |
Why?
|
| Postprandial Period | 1 | 2010 | 9 | 0.390 |
Why?
|
| Triazoles | 1 | 2011 | 85 | 0.390 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2010 | 26 | 0.380 |
Why?
|
| Hypertension | 2 | 2014 | 770 | 0.370 |
Why?
|
| Treatment Outcome | 7 | 2011 | 1349 | 0.370 |
Why?
|
| Injections | 3 | 2019 | 35 | 0.360 |
Why?
|
| Breath Tests | 1 | 2009 | 24 | 0.360 |
Why?
|
| Prevalence | 5 | 2017 | 1425 | 0.360 |
Why?
|
| Carbon Isotopes | 1 | 2009 | 38 | 0.360 |
Why?
|
| Depressive Disorder | 1 | 2011 | 166 | 0.350 |
Why?
|
| Follow-Up Studies | 3 | 2020 | 964 | 0.350 |
Why?
|
| Cohort Studies | 3 | 2019 | 1422 | 0.350 |
Why?
|
| Drug Administration Schedule | 4 | 2014 | 145 | 0.350 |
Why?
|
| Hospitalization | 3 | 2008 | 370 | 0.350 |
Why?
|
| Needles | 1 | 2008 | 8 | 0.340 |
Why?
|
| Thyrotropin | 1 | 2008 | 15 | 0.330 |
Why?
|
| Cholecalciferol | 2 | 2021 | 19 | 0.330 |
Why?
|
| Diabetic Angiopathies | 3 | 2020 | 20 | 0.320 |
Why?
|
| Glyburide | 1 | 2007 | 8 | 0.310 |
Why?
|
| Managed Care Programs | 1 | 2007 | 35 | 0.290 |
Why?
|
| Insulin, Long-Acting | 2 | 2020 | 3 | 0.290 |
Why?
|
| Islam | 1 | 2006 | 14 | 0.280 |
Why?
|
| Treatment Failure | 2 | 2019 | 65 | 0.280 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2014 | 984 | 0.270 |
Why?
|
| Drug Costs | 2 | 2020 | 28 | 0.270 |
Why?
|
| Venoms | 1 | 2005 | 15 | 0.270 |
Why?
|
| Hemoglobins, Abnormal | 1 | 2005 | 5 | 0.270 |
Why?
|
| Medicine, Ayurvedic | 1 | 2004 | 5 | 0.260 |
Why?
|
| Reagent Strips | 1 | 2004 | 3 | 0.250 |
Why?
|
| Community Health Centers | 2 | 2005 | 45 | 0.250 |
Why?
|
| Costs and Cost Analysis | 2 | 2020 | 54 | 0.250 |
Why?
|
| Body Mass Index | 2 | 2023 | 775 | 0.250 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2004 | 12 | 0.250 |
Why?
|
| Phytotherapy | 1 | 2004 | 62 | 0.240 |
Why?
|
| Arteriosclerosis | 1 | 2004 | 35 | 0.240 |
Why?
|
| Medication Adherence | 2 | 2017 | 165 | 0.240 |
Why?
|
| Peer Review, Research | 1 | 2003 | 10 | 0.240 |
Why?
|
| Specialties, Nursing | 1 | 2003 | 1 | 0.240 |
Why?
|
| Inpatients | 1 | 2004 | 72 | 0.240 |
Why?
|
| Depression | 1 | 2009 | 664 | 0.230 |
Why?
|
| Enalapril | 1 | 2002 | 6 | 0.230 |
Why?
|
| Gastric Inhibitory Polypeptide | 1 | 2022 | 1 | 0.230 |
Why?
|
| Vitamins | 2 | 2021 | 91 | 0.220 |
Why?
|
| Peptides | 1 | 2005 | 308 | 0.220 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2002 | 64 | 0.220 |
Why?
|
| Glucose | 2 | 2017 | 217 | 0.210 |
Why?
|
| Young Adult | 4 | 2014 | 4012 | 0.210 |
Why?
|
| Canada | 1 | 2022 | 121 | 0.210 |
Why?
|
| Periodicals as Topic | 1 | 2002 | 48 | 0.200 |
Why?
|
| Risk | 2 | 2017 | 256 | 0.200 |
Why?
|
| Pregnancy | 2 | 2020 | 1503 | 0.190 |
Why?
|
| Europe | 4 | 2014 | 88 | 0.190 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2019 | 9 | 0.180 |
Why?
|
| Practice Guidelines as Topic | 3 | 2007 | 187 | 0.180 |
Why?
|
| Time Factors | 2 | 2019 | 1681 | 0.180 |
Why?
|
| Nutrition Surveys | 2 | 2014 | 228 | 0.180 |
Why?
|
| Antimalarials | 1 | 2019 | 48 | 0.180 |
Why?
|
| Family Characteristics | 1 | 2020 | 102 | 0.170 |
Why?
|
| Sex Factors | 2 | 2014 | 859 | 0.170 |
Why?
|
| Community Health Services | 2 | 2014 | 175 | 0.160 |
Why?
|
| Disease Progression | 1 | 2020 | 580 | 0.160 |
Why?
|
| Aged, 80 and over | 2 | 2014 | 2333 | 0.160 |
Why?
|
| Injections, Subcutaneous | 1 | 2017 | 34 | 0.150 |
Why?
|
| Pilot Projects | 1 | 2019 | 628 | 0.150 |
Why?
|
| Mass Screening | 2 | 2014 | 427 | 0.150 |
Why?
|
| Prognosis | 1 | 2019 | 707 | 0.150 |
Why?
|
| Drug Industry | 1 | 2016 | 13 | 0.140 |
Why?
|
| History, 20th Century | 1 | 2016 | 110 | 0.140 |
Why?
|
| Los Angeles | 4 | 2005 | 368 | 0.140 |
Why?
|
| Prospective Studies | 1 | 2019 | 1353 | 0.130 |
Why?
|
| Quality Assurance, Health Care | 2 | 2007 | 55 | 0.130 |
Why?
|
| California | 2 | 2007 | 436 | 0.130 |
Why?
|
| Dietary Supplements | 2 | 2014 | 196 | 0.120 |
Why?
|
| Medical History Taking | 1 | 2014 | 33 | 0.120 |
Why?
|
| Overweight | 1 | 2016 | 233 | 0.120 |
Why?
|
| Tissue Distribution | 1 | 2014 | 197 | 0.120 |
Why?
|
| Waist Circumference | 1 | 2014 | 82 | 0.120 |
Why?
|
| Patient Satisfaction | 1 | 2014 | 141 | 0.120 |
Why?
|
| Lipids | 1 | 2014 | 222 | 0.110 |
Why?
|
| Behavior Therapy | 1 | 2014 | 145 | 0.110 |
Why?
|
| Health Status | 1 | 2014 | 356 | 0.100 |
Why?
|
| Retrospective Studies | 2 | 2007 | 1961 | 0.100 |
Why?
|
| Adolescent | 2 | 2011 | 5035 | 0.100 |
Why?
|
| Socioeconomic Factors | 1 | 2014 | 1003 | 0.090 |
Why?
|
| C-Peptide | 1 | 2009 | 6 | 0.090 |
Why?
|
| Placebos | 1 | 2009 | 38 | 0.090 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2009 | 18 | 0.090 |
Why?
|
| Insulin-Secreting Cells | 1 | 2009 | 27 | 0.090 |
Why?
|
| Carbon Dioxide | 1 | 2009 | 78 | 0.090 |
Why?
|
| Sensitivity and Specificity | 2 | 2008 | 555 | 0.090 |
Why?
|
| Cholesterol, HDL | 1 | 2009 | 87 | 0.080 |
Why?
|
| Regression Analysis | 1 | 2010 | 429 | 0.080 |
Why?
|
| Diabetic Nephropathies | 1 | 2009 | 53 | 0.080 |
Why?
|
| Population Surveillance | 1 | 2010 | 231 | 0.080 |
Why?
|
| Predictive Value of Tests | 1 | 2009 | 424 | 0.080 |
Why?
|
| Health Surveys | 1 | 2010 | 358 | 0.080 |
Why?
|
| Administration, Oral | 1 | 2008 | 212 | 0.080 |
Why?
|
| Chronic Disease | 1 | 2011 | 469 | 0.080 |
Why?
|
| Nurses | 1 | 2007 | 44 | 0.080 |
Why?
|
| Body Weight | 1 | 2009 | 404 | 0.080 |
Why?
|
| ROC Curve | 1 | 2007 | 138 | 0.080 |
Why?
|
| Focus Groups | 2 | 2005 | 307 | 0.070 |
Why?
|
| Age Factors | 1 | 2010 | 1007 | 0.070 |
Why?
|
| Lung | 1 | 2009 | 413 | 0.070 |
Why?
|
| Patient Care Planning | 1 | 2006 | 14 | 0.070 |
Why?
|
| Dietary Carbohydrates | 1 | 2006 | 30 | 0.070 |
Why?
|
| Angina, Unstable | 1 | 2005 | 8 | 0.070 |
Why?
|
| Drug Approval | 1 | 2005 | 6 | 0.070 |
Why?
|
| United States Food and Drug Administration | 1 | 2005 | 22 | 0.070 |
Why?
|
| Weight Gain | 1 | 2006 | 128 | 0.070 |
Why?
|
| Arizona | 1 | 2005 | 92 | 0.070 |
Why?
|
| Marketing | 1 | 2005 | 38 | 0.070 |
Why?
|
| Triglycerides | 1 | 2005 | 129 | 0.060 |
Why?
|
| Continuity of Patient Care | 1 | 2005 | 90 | 0.060 |
Why?
|
| Age of Onset | 1 | 2004 | 98 | 0.060 |
Why?
|
| Patient Compliance | 1 | 2005 | 202 | 0.060 |
Why?
|
| Sexual Behavior | 1 | 2009 | 587 | 0.060 |
Why?
|
| Single-Blind Method | 1 | 2003 | 50 | 0.060 |
Why?
|
| Medicare | 1 | 2005 | 188 | 0.060 |
Why?
|
| Electrocardiography | 1 | 2004 | 154 | 0.060 |
Why?
|
| Reference Values | 1 | 2003 | 204 | 0.060 |
Why?
|
| Guideline Adherence | 1 | 2003 | 82 | 0.060 |
Why?
|
| Length of Stay | 1 | 2004 | 184 | 0.060 |
Why?
|
| Myocardial Infarction | 1 | 2005 | 221 | 0.060 |
Why?
|
| Interprofessional Relations | 1 | 2003 | 48 | 0.060 |
Why?
|
| Proteinuria | 1 | 2002 | 48 | 0.060 |
Why?
|
| Heart Failure | 1 | 2005 | 230 | 0.060 |
Why?
|
| Anxiety | 1 | 2009 | 705 | 0.060 |
Why?
|
| Data Interpretation, Statistical | 1 | 2003 | 111 | 0.050 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2003 | 77 | 0.050 |
Why?
|
| Coronary Disease | 1 | 2003 | 113 | 0.050 |
Why?
|
| Educational Status | 1 | 2003 | 295 | 0.050 |
Why?
|
| Apoptosis | 1 | 2009 | 1317 | 0.050 |
Why?
|
| Communication | 1 | 2003 | 170 | 0.050 |
Why?
|
| Diagnosis, Differential | 1 | 2002 | 211 | 0.050 |
Why?
|
| Patient Selection | 1 | 2002 | 154 | 0.050 |
Why?
|
| Urban Population | 1 | 2003 | 318 | 0.050 |
Why?
|
| Homeostasis | 1 | 2014 | 172 | 0.030 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2012 | 4 | 0.030 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2008 | 6 | 0.020 |
Why?
|
| Competency-Based Education | 1 | 2005 | 9 | 0.020 |
Why?
|
| Child | 1 | 2012 | 2875 | 0.020 |
Why?
|
| Pravastatin | 1 | 2003 | 6 | 0.010 |
Why?
|
| Lovastatin | 1 | 2003 | 10 | 0.010 |
Why?
|
| Heptanoic Acids | 1 | 2003 | 12 | 0.010 |
Why?
|
| Fatty Acids, Monounsaturated | 1 | 2003 | 18 | 0.010 |
Why?
|
| Simvastatin | 1 | 2003 | 28 | 0.010 |
Why?
|
| Pyrroles | 1 | 2003 | 54 | 0.010 |
Why?
|
| Community-Institutional Relations | 1 | 2005 | 171 | 0.010 |
Why?
|
| Health Personnel | 1 | 2005 | 200 | 0.010 |
Why?
|
| Indoles | 1 | 2003 | 154 | 0.010 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2005 | 790 | 0.010 |
Why?
|